Clinical trials: HIV-Associated Lipodystrophy Syndrome
HIV Infections, HIV-Associated Lipodystrophy Syndrome
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
The purpose of this study is to assess the prevalence of metabolic and physical abnormalities in HIV infected (via mother-to-child transmission) and uninfected children and youth.
- Conditions
- HIV Infections, HIV-Associated Lipodystrophy Syndrome, HIV Lipodystrophy Syndrome, Lipodystrophy
- Trial name
- NCT00069004
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-Associated Lipodystrophy Syndrome
Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE
Treatment of facial lipoatrophy with dermal injections polylactic acid (Newfill TM) is a safe procedure and has been now widely used with a good efficacy.
- Trial name
- NCT00383734
- Testing
- Newfill, Eutrophill
- Where
- France
- Volunteers
- 148 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-Associated Lipodystrophy Syndrome
Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Aim: To assess the safety on the progression of HIV infection and the efficacy on the evolution of metabolic parameters and body fat of either viral load- or CD4 cell-driven strategies of intermittent treatment in chronically…
- Trial name
- NCT00646984
- Testing
- Standard continuous antiretroviral therapy, CD-4 guided therapy interruption, Viral load driven treatment interruption
- Where
- Spain
- Volunteers
- 147 people
- Sponsor
- Hospital Clinic of Barcelona
HIV-Associated Lipodystrophy Syndrome
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Trial name
- NCT00135460
- Testing
- nucleoside analogue sparing HAART regimen
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
HIV Infections, HIV-Associated Lipodystrophy Syndrome
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
The aim of this randomized study is to compare the occurrence of lipoatrophy in HIV-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy with…
- Trial name
- NCT00122668
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor
- Where
- France
- Volunteers
- 112 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infection, Antiretroviral Side Effects
Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy
Combined antiretroviral therapy (cART) is associated with facial lipoatrophy, which is potentially stigmatizing for HIV-positive patients.
- Conditions
- HIV Infection, Antiretroviral Side Effects, Lipodystrophy Syndrome Related to HIV Infection
- Trial name
- LIPOPHILL (NCT01077765)
- Testing
- Eutrophill
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV, HIV-Infections
The Visceral Adiposity Measurement and Observation Study
The Visceral Adiposity Measurement and Observation Study
- Conditions
- HIV, HIV-Infections, HIV-1-infection, HIV I Infection
- Trial name
- VAMOS (NCT05383456)
- Testing
- Diagnostic Test, HIV Anti-retroviral Background Therapy
- Where
- 8 sites in United States
- Volunteers
- 196 people
- Sponsor
- Theratechnologies
Lipodystrophy, HIV Infections
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
- Trial name
- NCT00608023
- Testing
- Tesamorelin
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 263 people
- Sponsor
- Theratechnologies
HIV-1-infection, Antiviral Drug Adverse Reaction
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir…
- Conditions
- HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities
- Trial name
- NCT04340388
- Testing
- Dolutegravir 50 MG, Antiretroviral/Anti HIV
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Augusta University
HIV I Infection, HIV Associated Lipodystrophy
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue.
- Conditions
- HIV I Infection, HIV Associated Lipodystrophy, Metabolic Syndrome, Aging
- Trial name
- NCT04887675
- Testing
- MRI
- Where
- Serbia
- Volunteers
- 120 people
- Sponsor
- University of Novi Sad
HIV Infections, HIV-Associated Lipodystrophy Syndrome
Follow-up on the HIGH: Low Study - the Longterm Effects of Growth Hormone
A follow-up study on the randomized, controlled, double-blind HIGH: low study. We will examine the participants from the HIGH: low study min. 6 months after finishing the HIGH: low study.
- Trial name
- NCT00662181
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- Hvidovre University Hospital
HIV Lipodystrophy
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
"HIV lipodystrophy syndrome" (HLS) is characterized by loss of fat in the arms and legs, with increase in fat in the abdomen, and abnormal blood lipid levels.
- Trial name
- NCT01511016
- Testing
- Human recombinant leptin ("metreleptin")
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine